Arrow-right Camera
News >  Health

The 34-year-old neuroscientist developing a drug to prevent depression and PTSD

Rebecca Brachman speaks at TED2017 about her work on a drug to prevent depression. (TED / Ryan Lash/TED)
Rebecca Brachman speaks at TED2017 about her work on a drug to prevent depression. (TED / Ryan Lash/TED)

VANCOUVER, British Columbia – Rebecca Brachman sat at a table in a quiet area of the convention center Monday evening when a man approached her.

“Your talk inspired me. I was really fascinated,” he told her. “I just wanted you to know that.”

This happened throughout the day at the TED2017 conference as Brachman adopted mini-celebrity status after she stood on stage here and told the audience she may have discovered a drug that could prevent mental illness. Since then, it was hard for her to navigate the halls without someone stopping her to commend her work.

For the 34-year-old neuroscientist at Columbia University, the positive reception to her research was surprising, yet she realized it shouldn’t be, given the statistics. If 1 in 5 people have a diagnosable mental health condition in a given year, then it’s likely that most people in the room had direct experience with some kind of psychological disorder, either personally or in someone they knew. And given that the World Health Organization recently named depression the leading cause of disability globally, a scientist advancing preventive medicine should be treated with rock star status.

In 2014, Brachman was studying emotional behaviors in mice when she accidentally stumbled upon what could be one of the biggest breakthroughs in mental health pharmacology. She had given some mice the drug ketamine, also known as special K, which has been tried as an antidepressant. Because the drug was known to wear off in a few hours and funds were tight, she ended up using some of the same mice for another study testing mice’s resilience under chronic stress conditions.

The mice that had previously taken the drug were completely inoculated from the types of depressive, withdrawn symptoms they typically exhibited after being put through several weeks of major stress-inducing scenarios. She ran it again and again, and discovered that the ketamine seemed to enhance stress resilience enough to ward off triggers that often hurt their mental health.

If it works in humans, she envisions the drug she’s developing could be used to give to soldiers in war or aid workers in disaster zones to manage their emotions in the aftermath. She’s not trying to “to make super soldiers without empathy,” she said in an interview after her talk, but instead prevent the onset of future depression or anxiety all too common among those who experience and witness trauma.

Brachman was first drawn to neuroscience in college. Though she originally went to Oberlin College planning to major in poetry, she said she’d always been interested in big ideas, idolizing people like Galileo and William Blake as a child, and the field of neuroscience was still ripe for new breakthroughs.

Now she stands at the precipice of what could be one of the biggest discoveries in mental health since antidepressants were developed in the 1950s.

Brachman was among two dozen TED Fellows chosen to present at the annual conference. The Fellows program provides them a platform for their ideas and access to the larger TED network. She said she hopes sharing her research not only drives interest, but also adds to the growing conversation around destigmatizing mental health. It’s only when society takes it as seriously as physical health that real progress will be made, she said.

With diagnoses of cancer and most other physical diseases, there is hope because of the medical treatments available. But in mental health, current treatments mostly just suppress the symptoms and the how and why they work are still being studied. Brachman said she’s seen firsthand the suffering of people in her life dealing with chronic depression or bipolar disorder and the hopelessness those illnesses can induce.

“I think once we have treatments for diseases, or preventions for them, it really changes the conversation. Things are stigmatized in part when there’s nothing you can do about it. They’re also mythologized when there’s nothing you can do about it,” she said. “From my experience, it’s more common than not. I’ve shifted my perspective from some people have mental illnesses to almost everyone I’ve ever met has had some direct experience.”

Brachman’s drug, which she said she plans to begin testing on humans next year, would be designed for those at risk of developing symptoms due to a stressful job or experience, not for people genetically predisposed to mental illness. But Brachman believes that if she can show it is possible to prevent, not just treat or mitigate, mental illness, then it could open the door for all kinds of new preventive medicine.

Though mental illness is just that, an illness, and deserves to be treated as such, Brachman also notes that stress resilience exists on a spectrum of severity depending on the individual and the circumstance, and there are lifestyle interventions that can often help manage symptoms. Like a patient with diabetes, their care is commonly paired with diet and exercise.

In her work with stressed out mice, exercise has been shown to be “almost as robust as the drugs” in managing their mental heath, she said.

However, she is not suggesting that people take their care entirely into their own hands if they are suffering from a serious mental illness. No one would tell a diabetic patient not to take their insulin. This is how she hopes her work can contribute to the shift in how people view the major health issue.

“How quickly we get any of these treatments will depend on how as a society we prioritize it,” she said. “If this is a problem that’s effecting that number of people … if other people can stand up and say this is important we have to do something, it gives urgency to that aspect of the conversation.”


Subscribe to the Morning Review newsletter

Get the day’s top headlines delivered to your inbox every morning by subscribing to our newsletter

There was a problem subscribing you to the newsletter. Double check your email and try again, or email webteam@spokesman.com

You have been successfully subscribed!